Publicaciones en colaboración con investigadores/as de Pierre and Marie Curie University (12)

2024

  1. Lack of association between classical HLA genes and asymptomatic SARS-CoV-2 infection

    Human Genetics and Genomics Advances, Vol. 5, Núm. 3

  2. New insights into the regulation of bile acids synthesis during the early stages of liver regeneration: A human and experimental study

    Biochimica et Biophysica Acta - Molecular Basis of Disease, Vol. 1870, Núm. 5

2023

  1. Artificial intelligence-based pathology as a biomarker of sensitivity to atezolizumab-bevacizumab in patients with hepatocellular carcinoma: a multicentre retrospective study

    The Lancet. Oncology, Vol. 24, Núm. 12, pp. 1411-1422

  2. Identification and experimental validation of druggable epigenetic targets in hepatoblastoma

    Journal of Hepatology, Vol. 79, Núm. 4, pp. 989-1005

  3. Rare predicted loss-of-function variants of type I IFN immunity genes are associated with life-threatening COVID-19

    Genome Medicine, Vol. 15, Núm. 1

2022

  1. 2022 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer, including patients with COVID-19

    The Lancet Oncology, Vol. 23, Núm. 7, pp. e334-e347

2021

  1. Assessing the impact of COVID-19 on liver cancer management (CERO-19)

    JHEP Reports, Vol. 3, Núm. 3

  2. Long noncoding RNA NIHCOLE promotes ligation efficiency of DNA double-strand breaks in hepatocellular carcinoma

    Cancer Research, Vol. 81, Núm. 19, pp. 4910-4925

2020

  1. Consensus guidelines for the definition, detection and interpretation of immunogenic cell death

    Journal for ImmunoTherapy of Cancer, Vol. 8, Núm. 1

  2. International and multicenter real-world study of sorafenib-treated patients with hepatocellular carcinoma under dialysis

    Liver International, Vol. 40, Núm. 6, pp. 1467-1476

2019

  1. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer

    The Lancet Oncology, Vol. 20, Núm. 10, pp. e566-e581

2013

  1. In vitro correction of a pseudoexon-generating deep intronic mutation in LGMD2A by antisense oligonucleotides and modified small nuclear RNAs

    Human Mutation, Vol. 34, Núm. 10, pp. 1387-1395